Allurion Technologies, Inc. Overview
Pro stress-test →Allurion Technologies focuses on ending obesity with a weight loss platform offering the Allurion Program—a swallowable, procedure-less intragastric balloon—and AI-powered remote patient monitoring tools through its Allurion Virtual Care Suite. The company achieved FDA premarket approval on February 23, 2026 for the Allurion Gastric Balloon System featuring the Allurion Smart Capsule.
Strategic Profile
Pro stress-test →The Smart Capsule is a non-surgical, 15-minute orally administered device that resides approximately 4 months in the stomach and targets adults with BMI 30-40, opening access to approximately 80 million Americans with obesity. The company is pursuing strategic partnerships for expansion in Latin American markets, including a partnership with Bionut in Argentina that integrates cutting-edge weight loss methods like the Smart Capsule.
Competitive Landscape
Pro stress-test →Allurion competes in the weight loss device and digital health market with its non-surgical balloon platform and AI-powered virtual care suite. Direct competitors include traditional bariatric surgery providers, GLP-1 medication manufacturers (Novo Nordisk's Mounjaro/tirzepatide), and other device makers. Allurion's differentiation lies in its procedure-less, swallowable approach combined with combination therapy strategies using lower-dose GLP-1 drugs.
Industry Context
Allurion Technologies, Inc. operates in Medical Devices & Digital Health - Obesity/Weight Loss Treatment.
Key facts
Founded: 2013 · Headquarters: Natick, Massachusetts, US · Revenue: $32.11M · Market cap: $14.37M